These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 37935564)

  • 1. Comprehensive analyses of immune tumor microenvironment in papillary renal cell carcinoma.
    de Vries-Brilland M; Rioux-Leclercq N; Meylan M; Dauvé J; Passot C; Spirina-Menand E; Flippot R; Fromont G; Gravis G; Geoffrois L; Chevreau C; Rolland F; Blanc E; Lefort F; Ravaud A; Gross-Goupil M; Escudier B; Negrier S; Albiges L
    J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37935564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of molecular subtypes based on chromatin regulator and tumor microenvironment infiltration characterization in papillary renal cell carcinoma.
    Tang Q; Pan D; Xu C; Chen L
    J Cancer Res Clin Oncol; 2023 Jan; 149(1):231-245. PubMed ID: 36404389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of papillary and clear cell renal cell carcinoma through imaging mass cytometry reveals distinct immunologic profiles.
    Govindarajan A; Salgia NJ; Li H; Castro DV; Mirzapoiazova T; Armstrong B; Zhao D; Mercier BD; Dizman N; Chawla N; Zengin Z; Meza L; Tripathi N; Sayegh N; Chehrazi-Raffle A; Tripathi A; Pal SK
    Front Immunol; 2023; 14():1182581. PubMed ID: 37638025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy.
    Büttner FA; Winter S; Stühler V; Rausch S; Hennenlotter J; Füssel S; Zastrow S; Meinhardt M; Toma M; Jerónimo C; Henrique R; Miranda-Gonçalves V; Kröger N; Ribback S; Hartmann A; Agaimy A; Stöhr C; Polifka I; Fend F; Scharpf M; Comperat E; Wasinger G; Moch H; Stenzl A; Gerlinger M; Bedke J; Schwab M; Schaeffeler E
    Genome Med; 2022 Sep; 14(1):105. PubMed ID: 36109798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cuproptosis-Related LncRNA-Based Prediction of the Prognosis and Immunotherapy Response in Papillary Renal Cell Carcinoma.
    Pang Y; Wang Y; Zhou X; Ni Z; Chen W; Liu Y; Du W
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.
    Zhou L; Fang H; Guo F; Yin M; Long H; Weng G
    J Clin Lab Anal; 2022 Aug; 36(8):e24582. PubMed ID: 35808868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling.
    Pal SK; Ali SM; Yakirevich E; Geynisman DM; Karam JA; Elvin JA; Frampton GM; Huang X; Lin DI; Rosenzweig M; Lipson D; Stephens PJ; Ross JS; Miller VA; Agarwal N; Shuch B; Choueiri TK; Chung JH
    Eur Urol; 2018 Jan; 73(1):71-78. PubMed ID: 28592388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated analysis of immune-related gene subtype and immune index for immunotherapy in clear cell renal cell carcinoma.
    Bai D; Chen S; Feng H; Yin A; Lu J; Ma Y; Sugiyama H
    Pathol Res Pract; 2021 Sep; 225():153557. PubMed ID: 34329838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrated Phenotypic/Genotypic Analysis of Papillary Renal Cell Carcinoma Subtypes: Identification of Prognostic Markers, Cancer-related Pathways, and Implications for Therapy.
    Saleeb RM; Plant P; Tawedrous E; Krizova A; Brimo F; Evans AJ; Wala SJ; Bartlett J; Ding Q; Boles D; Rotando F; Farag M; Yousef GM
    Eur Urol Focus; 2018 Sep; 4(5):740-748. PubMed ID: 28753789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three-gene risk model in papillary renal cell carcinoma: a robust likelihood-based survival analysis.
    Wang Y; Yan K; Lin J; Wang J; Zheng Z; Li X; Hua Z; Bu Y; Shi J; Sun S; Li X; Liu Y; Bi J
    Aging (Albany NY); 2020 Nov; 12(21):21854-21873. PubMed ID: 33154194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of 4-genes model in papillary renal cell tumor microenvironment based on comprehensive analysis.
    Luo L; Zhou H; Su H
    BMC Cancer; 2021 May; 21(1):553. PubMed ID: 33993869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioinformatics profiling integrating a four immune-related long non-coding RNAs signature as a prognostic model for papillary renal cell carcinoma.
    Liu Y; Gou X; Wei Z; Yu H; Zhou X; Li X
    Aging (Albany NY); 2020 Jul; 12(15):15359-15373. PubMed ID: 32716909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Cell Infiltration and Identifying Genes of Prognostic Value in the Papillary Renal Cell Carcinoma Microenvironment by Bioinformatics Analysis.
    Liu T; Zhang M; Sun D
    Biomed Res Int; 2020; 2020():5019746. PubMed ID: 32775427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial.
    Negrier S; Rioux-Leclercq N; Ferlay C; Gross-Goupil M; Gravis G; Geoffrois L; Chevreau C; Boyle H; Rolland F; Blanc E; Ravaud A; Dermeche S; Flechon A; Albiges L; Pérol D; Escudier B;
    Eur J Cancer; 2020 Apr; 129():107-116. PubMed ID: 32146304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of prognostic biomarkers in papillary renal cell carcinoma and PTTG1 may serve as a biomarker for predicting immunotherapy response.
    Tian X; Xu WH; Xu FJ; Li H; Anwaier A; Wang HK; Wan FN; Zhu Y; Cao DL; Zhu YP; Shi GH; Qu YY; Zhang HL; Ye DW
    Ann Med; 2022 Dec; 54(1):211-226. PubMed ID: 35037540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-cell transcriptomics reveals a low CD8
    Peng YL; Xiong LB; Zhou ZH; Ning K; Li Z; Wu ZS; Deng MH; Wei WS; Wang N; Zou XP; He ZS; Huang JW; Luo JH; Liu JY; Jia N; Cao Y; Han H; Guo SJ; Dong P; Yu CP; Zhou FJ; Zhang ZL
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35121646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of potential biomarkers associated with immune infiltration in papillary renal cell carcinoma.
    Deng R; Li J; Zhao H; Zou Z; Man J; Cao J; Yang L
    J Clin Lab Anal; 2021 Nov; 35(11):e24022. PubMed ID: 34606125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective study.
    de Vries-Brilland M; Gross-Goupil M; Seegers V; Boughalem E; Beuselinck B; Thibault C; Chevreau C; Ladoire S; Barthélémy P; Negrier S; Borchiellini D; Huillard O; Geoffrois L; Gravis G; Saldana C; Thiery-Vuillemin A; Escudier B; Ravaud A; Albiges L
    Eur J Cancer; 2020 Sep; 136():76-83. PubMed ID: 32653774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multi-omics and immunogenomics analysis revealed PFKFB3 as a targetable hallmark and mediates sunitinib resistance in papillary renal cell carcinoma: in silico study with laboratory verification.
    Lu Z; Pan Y; Wang S; Wu J; Miao C; Wang Z
    Eur J Med Res; 2024 Apr; 29(1):236. PubMed ID: 38622715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advanced papillary renal cell carcinoma: Epidemiology, genomic drivers, current therapies, and ongoing trials.
    Sweeney PL; Jang A; Halat SK; Pal SK; Barata PC
    Cancer Treat Res Commun; 2022; 33():100639. PubMed ID: 36162322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.